Abstract Aims To evaluate the clinical and economic value of onabotulinumtoxinA (onabotA) vs oral pharmacotherapies for adults with OAB inadequately managed with anticholinergics from a United States (US) Medicare + societal perspective over 1 year. Materials and methods A Markov model-based 1-year cost per responder (CPR) analysis was conducted for patients achieving complete response (100% reduction in urinary incontinence episodes [i.e. complete dryness]). Comparators incl

ABSTRACT Objective To examine population-based trends in utilization of minimally invasive therapies (MITs) for overactive bladder (OAB) stratified by age and frailty among Medicare beneficiaries. Methods This population-based study used a 20% sample of fee-for-service Medicare beneficiaries to investigate rates of utilization for MIT for OAB [onabotulinumtoxinA injections (BTX), percutaneous tibial nerve stimulation (PTNS), and sacral neuromodulation (SNM)] from 2015 to 2020

Abstract Introduction: The assessment of neurogenic lower urinary tract dysfunction (NLUTD) should include objective and quality of life (QoL) measures, considering sex and gender differences. Thus, we investigated the sex-specific impact of NLUTD on QoL. Methods: We evaluated consecutive outpatients with chronic NLUTD, who had completed the Short Form (SF)-Qualiveen questionnaire from September 2024 to January 2026 at a specialized spinal cord injury center, in a cross-secti